Serum hsCRP and IL-6 as prognostic markers in Somatic Symptom Disorder and Related Disorders. A prospective cohort study.

Activity: Talk or presentationLecture

Description

DSM-5 Somatic symptom disorder and related disorders (SSRD) affect approximately 5-7% of the population. Is characterised by at least six months of somatic symptoms accompanied by distress, excessive thoughts, feelings and behaviours in response to these somatic symptoms.
These conditions include, amongst others, somatic symptom disorder (SSD), conversion disorder or functional neurological disorder (CD/FND), and illness anxiety disorder. The pathophysiology remains poorly understood.
We focused on a possible biological explanation in the etiology of SSRD, which may involve chronic systemic low-grade-inflammation (SLI). We therefore aimed to explore the relationship between baseline serum hsCRP and IL-6 on physical symptoms, anxiety, depression, an pain in SSRD patients after treatment. To explore the roles of hsCRP and IL-6 as prognostic markers for treatment outcome in SSRD.
Period10 Nov 2022
Event titleWorld Psychiatric Association (WPA) Thematic Congress
Event typeConference